Device Firms Want Their Own Guidelines On Risk Information In Ads
FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed
More from Archive
More from Medtech Insight
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.